Diasorin products

DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated scientists DiaSorin has been able to promptly deliver diagnostic solutions to manage the COVID-19 pandemic emergency.

Epstein Barr Virus (EBV) is a member of the herpes virus family and is the causative agent of infectious mononucleosis. Typical serological assays measure IgG and IgM antibodies directed against different components of EBV. Viral Capsid (VCA) are used to detect antibodies generally produced during the acute phase of the infection whereas the EBNA-1 protein is used to detect IgG produced during convalescence. IgG to the early antigen D (EA-D) appears in the acute phase and generally falls to undetectable levels after 3 to 6 months. In many people, detection of antibody to the early antigen is a sign of active infection, but in 20-30% of healthy individuals IgG to EA-D remain detectable for life. EA rises again if reactivation of infection occurs. It has also been demonstrated that IgM antibodies to VCA components of EBV tend to persist for several months after the infection in 5 to 10% of the cases.

Sepsis can be difficult to distinguish from other non-infectious conditions in critically ill patients with clinical sign of acute inflammation. However, therapies and outcomes may differ significantly between patients with and without sepsis. Among the potentially available laboratory parameters, Procalcitonin (PCT) has the highest diagnostic accuracy. PCT levels rise rapidly as a response to severe systemic infections and sepsis. This allowing clinicians to differentiate sepsis from other non-infectious conditions. Levels of PCT tested can properly address antibiotics therapy. Having an accurate PCT level will allow correct dosing of antibiotic therapy. In conjunction with other laboratory findings PCT levels can help in identifying systemic bacterial infections (sepsis) from severe sepsis and/or septic shock. For each category of illnesses an appropriate clinical cut-off is to be used.

DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated scientists, DiaSorin has developed a new concept assay to maximize EARLY Lyme borreliosis detection through a unique combination of humoral and cell mediated immunity. The unique diagnostic value of B cells combined with T cells. LIAISON^® LymeDetect^® is an innovative approach to EARLY Lyme disease diagnostics that combines LIAISON^® Borrelia IgG and IgM CLIA assays, with the patented QuantiFERON^® IGRA technology. This potent combination ensures effective diagnosis of Lyme disease within weeks of contact with an infected tick, with concrete benefits for physicians, patients and laboratories.

The LIAISON^® Borrelia IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to Borrelia burgdorferi sensu lato in human serum, plasma or cerebrospinal fluid (CSF) samples. The test has to be performed on the LIAISON^® analyzer family.